Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RC48-C016
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- NCT05302284 ↗
- Recruiting
- RemeGen Co., Ltd.
- Standard
We haven't built an HCP commentary report on RC48-C016 (RC48-ADC, toripalimab and 3 more in Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RC48-C016 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| YouTube | 3 | |
| Podcasts | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Urothelial Carcinoma; HER2-expressing
- Interventions
- RC48-ADC; Toripalimab; Gemcitabine; Cisplatin; Carboplatin
- Arms
- RC48-ADC + JS001 · Experimental
- Gemcitabine + cisplatin/carboplatin · Active comparator
- Enrollment
- 452 (estimated)
- Primary outcomes
- Progression-free survival (PFS), evaluated by independent review committee
- Overall survival (OS)
- Sponsor
- RemeGen Co., Ltd.
- Start
- Jun 14, 2022
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05302284 · updated Dec 18, 2023
Publications
linked from the registry- Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, Li J, Shi Y, Yao K, Hu B, Liu Z, Liao H, Yu Z, Jin B, Zhao P, Yang T, Liu X, Qin Y, Xue X, Gou X, Huang J, Gu J, Qi X, Zhang L, Ma G, Liu B, Fang J, Jiang S, He Z, Zhou A, Guo J; RC48-C016 Trial Investigators. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med. 2025 Dec 11;393(23):2324-2337. doi: 10.1056/NEJMoa2511648. Epub 2025 Oct 19. PubMed 41124210